DataMeds AI, Inc. (NASDAQ: MEDS) has approximately 36.2 million shares of potential dilution waiting in the wings, roughly 12.8 times its current tradeable float of about 2.83 million shares. The company's dilution risk grade is 9 out of 10, the highest tier ShareStructure assigns.
The number is not theoretical. It is sourced from a single S-1/A registration statement filed November 10, 2026, covering 34.46 million shares for resale — meaning the holders can sell into the open market once the SEC declares it effective — plus additional convertible and share-settled obligations disclosed in the most recent 10-Q.
The Convertible Notes at the Core
The largest piece is $20.3 million in senior secured convertible notes issued in May 2026. These notes carry a 20% original issue discount — meaning the investors paid $0.80 for every $1.00 of face value — and convert at the lesser of $6.00 or the prior day's closing price, with a floor of $1.00. At recent trading levels, the notes are already pressing against that floor, implying roughly 20.3 million conversion shares. That alone is 3.6 times the company's 5.72 million shares outstanding.
But the floor is temporary. Once the S-1 is declared effective and a new Series A Preferred Stock is authorized, the notes convert automatically into preferred shares whose floor resets to 20% of the prior close — effectively removing the ceiling on dilution. A 10% PIK dividend — meaning interest paid in additional preferred shares rather than cash — accretes to the stated value every six months, compounding the share count further. The company's own S-1/A illustrates 42.3 million shares at $0.50 and states that $0.50 is not a floor.
Silverback and Ongoing Issuance
Separately, Silverback Capital is issuing free-trading shares under a Section 3(a)(10) court-approved settlement — a process that lets a company issue unregistered shares to satisfy creditor claims after a court hearing, bypassing normal SEC registration. In Q3 2026 alone, Silverback received 1.59 million shares to cover $1.26 million of claims. Roughly $7.5 million of the original claim pool may remain, which at recent effective pricing implies up to 9 million additional shares.
Share Count Already Accelerating
Shares outstanding have grown 219% over the past 12 months on a split-adjusted basis, rising from 1.79 million to 5.72 million — despite a 1-for-50 reverse split in May 2026. The 87% increase from August to November 2026 alone came from Silverback tranches, vendor payable conversions, and acquisition-related issuances.
The company holds $476,598 in cash against a quarterly burn rate of roughly $1.98 million, leaving minimal runway without further capital raises. Every financing round since October 2024 has involved equity-linked instruments: merchant cash advances, OID notes, 3(a)(10) settlements, VWAP-settled acquisitions, and variable-rate convertibles. The pattern has repeated roughly every one to four months.
What Gates Remain
Two structural gates currently slow the conversion wave. First, a 19.99% exchange cap — a Nasdaq rule limiting share issuance without stockholder approval — restricts May Note conversions to approximately 502,000 shares. A stockholder meeting is due by roughly November 25, 2026, and approval would lift that cap. Second, the S-1 cannot be declared effective until a blank-check preferred amendment and the Series A certificate of designation are filed.
Once both gates open, 34.46 million registered shares become immediately resaleable — against an authorized share ceiling of 500 million, which provides ample room.
The company disclosed on November 3, 2026, that it terminated a letter of intent with EOS, Scilex, and Datavault that would have issued roughly 89.5% of the fully diluted company to outside parties. That removes one source of threatened dilution but leaves every existing convertible, warrant, and share-settled liability intact.